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 Systemic treatment of an antibody-based
glucagon receptor antagonist confers
cardioprotection against myocardial
infarction and post-myocardial infarction
remodeling in mice.
 Systemic treatment of glucagon receptor
antagonist prevents pressure overload
induced cardiac remodeling and
dysfunction in mice.
 Glucagon receptor antagonist treatment
attenuates the pathological progression
of heart failure induced by pressure
overload in mice.
 Long-term suppression of glucagon
signaling is potentially an effective
therapy for heart failure with different
etiologies independent of metabolic
disorders.https://doi.org/10.1016/j.jacbts.2018.11.001
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162SUMMARYat
nd
as
reMice were treated with a fully human monoclonal glucagon receptor antagonistic antibody REMD2.59 following
myocardial infarction or pressure overload. REMD2.59 treatment blunted cardiac hypertrophy and fibrotic
remodeling, and attenuated contractile dysfunction at 4 weeks after myocardial infarction. In addition, REMD2.59
treatment at the onset of pressure overload significantly suppressed cardiac hypertrophy and chamber dilation
with marked preservation of cardiac systolic and diastolic function. Initiation of REMD2.59 treatment 2 weeks after
pressure overload significantly blunted the progression of cardiac pathology. These results provide the first in vivo
proof-of-concept evidence that glucagon receptor antagonism is a potentially efficacious therapy to ameliorate
both onset and progression of heart failure. (J Am Coll Cardiol Basic Trans Science 2019;4:161–72) © 2019 The
Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).H eart failure affects approximately 6.5million people over 20 years of age in theUnited States, with its prevalence esti-
mated to increase about 45% by 2030 to almost 8
million (1). It is a chronic disease with complex etiol-
ogy and heterogeneity in its pathological manifesta-
tions. Major risk factors for heart failure include
smoking, hypertension, and obesity, as well as life-
style and dietary influences. Despite significant
advancement in the standard care of heart failure,
the 5-year mortality rate of the disease remains at
nearly 50% (1). The new effective therapies for heart
failure are critically needed for such a major unmet
need.SEE PAGE 173Glucagon (GLC) is a peptide hormone produced by
pancreatic a-cells (2–6). As a major catabolic hor-
mone, GLC stimulates glucose production from
glycogen in liver and promotes gluconeogenesis
while it inhibits glycolysis and glycogen synthesis (4).
It increases blood glucose and energy expenditure as
part of the energy mobilization process in response to
hypoglycemia and other bioenergetic stress. Conse-
quently, GLC serves as a counterbalancing hormone
with insulin to regulate glucose homeostasis
depending on nutrient conditions and available en-
ergy sources (7). The GLC receptor (GCGR) is a mem-
ber of the G protein–coupled receptor family (3,6,8,9).
The canonical function of GCGR elicited by GLC is
mediated by G protein–coupled protein kinase A
activation; however, tissue-specific function of GCGR
has been implicated in different cellular processes
(2,3,10). Elevated GLC is observed in chronictest they are in compliance with human studies committees
Food and Drug Administration guidelines, including patient co
ic to Translational Science author instructions page.
ceived April 2, 2018; revised manuscript received November 1hyperglycemia associated with type 1 or type 2 dia-
betes (11–13). Overactivated GLC signaling may
contribute to disease progression of diabetes by
enhancing glucose production and aggravating sys-
temic hyperglycemia, as well as impairing insulin
signaling. Therefore, GCGR inhibition, using either
small molecules or antagonistic antibodies, is poten-
tially efficacious to treat diabetes as demonstrated in
both preclinical studies as well as several recent
clinical trials (11–21). However, much of the previous
studies on GLC signaling are in the liver and brain,
involving glucose metabolic regulation (2,3,22). Its
specific and cell-autonomous role in cardiac tissue
has just begun to be appreciated.
Other than glucose regulation in liver, GCGR is also
widely expressed in multiple other tissues, including
the heart (3,15,18,23–28). In a recent study by Ali et al.
(29), GLC stimulation was shown to promote ischemia
injury in mouse heart while cardiomyocyte specific
GCGR inactivation protected the heart from patho-
logical remodeling following myocardial infarction.
This study highlights the potential cardiomyocyte
cell-autonomous effect of GCGR overactivation in
cardiac pathological remodeling, and GCGR antago-
nism as a potential therapy for heart failure. REMD-
477 is a fully human anti-GCGR antibody that
competitively blocks GLC binding to the GCGR with
30-pM binding affinity, and can effectively inhibit the
receptor activity at low nanomolar concentrations in
cell-based functional assays (14,17,20). Compared
with small-molecule approaches (30), antibody-based
GCGR antagonism such as REMD-477 is a competitive
antagonist and does not have deleterious effects on
serum lipid profiles (11,12,19,21,31). Finally, REMD-477and animal welfare regulations of the authors’ in-
nsent where appropriate. For more information, visit
, 2018, accepted November 2, 2018.
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163has been shown to be safe in a phase I study
(NCT02715193) and is being tested in 2 phase II clinical
studies (NCT03117998 and NCT02455011 for type 1 and
type 2 diabetes, respectively). In short, anti-GCGR
antibody offers a novel tool to effectively and specif-
ically inhibit GCGR with proven record of clinical
safety and efficacy at molecular and metabolic levels.
Functionally identical as REMD-477, REMD2.59 is a
surrogate human antibody specifically generated for
preclinical studies in rodents (32). In a recent study,
weekly treatment with REMD2.59 is shown to reverse
diabetes in ob/ob mice and improves cardiac function
associated with diabetic cardiomyopathy (32).
Although this study supports the cardioprotective
effect of GCGR antagonism, it is not clear whether the
beneficial effect is a direct consequence of car-
dioprotection on cardiomyocyte or an indirect result
of improved global glucose homeostasis and insulin
signaling. In the current study, we employed 2
mechanistically divergent and diabetes-independent
murine disease models for heart failure, myocardial
infarction, and pressure overload, to test whether the
cardioprotection by the GCGR antibody is the primary
effect of the receptor inhibition. Based on morpho-
logical, functional, and molecular parameters, treat-
ment with GCGR antibody REMD2.59 significantly
ameliorated the development of heart failure, by
attenuating pathological remodeling and cardiac hy-
pertrophy while preventing functional deterioration
and pathological gene expression. These novel and
exciting observations implicate a potential role of
GLC-mediated signaling in heart failure via a car-
diomyocyte cell-autonomous mechanism. It raises
the prospect of targeting GCGR as potential therapy to
treat common forms of heart failure independent of
the confounding status of global glucose metabolic
disorders.
METHODS
ANIMALS. C57BL/6 male mice (Jackson Laboratory,
Bar Harbor, Maine) were used in this study, and all
mice were housed in groups of 4 to 5 mice per cage in
a room maintained at 23  1C and 55  5% humidity
with a 12-h light-dark cycle and given ad libitum ac-
cess to food and water.
MYOCARDIAL INFARCTION. Myocardial infarction
(MI) was induced in mice by ligation of the left
anterior coronary artery. Briefly, the chest was
opened via a left thoracotomy. The left coronary ar-
tery was identified visually using a stereo micro-
scope, and a 7-0 suture (Ethicon, Inc., Somerville,
New Jersey) was placed around the artery 1 to 2 mm
below the left auricle. The electrocardiogram wasmonitored continuously. Permanent occlusion of the
left coronary artery resulted from its ligation with the
suture. Myocardial ischemia was confirmed by pallor
in heart color and ST-segment elevation. The chest
was closed with 6-0 silk suture. Once spontaneous
respiration resumed, the endotracheal tube was
removed.
TRANSAORTIC CONSTRICTION. In the transaortic
constriction (TAC) study, after intubation using a 20-
gauge plastic needle, mice were placed on a volume
ventilator (80 breaths/min, 1.2 ml/g/min) and the
anesthesia maintained by isoflurane. The chest was
opened via a limited incision in the third intercostal
space. The aorta was identified at the T8 region. A 6-
0 silk suture was passed around the transverse aorta
and tightened against a 27-gauge needle followed by
the removal of the needle. Pressure gradient was
evaluated by transaortic Doppler.
TREATMENT PROTOCOL. For the MI study, a total of
56 C57BL/6 male mice 8 to 10 weeks of age were
operated on by occluding the left anterior coronary
artery. Then they were randomly divided into 3
groups: 1) vehicle-treated (phosphate-buffered saline
[PBS]) control mice (n ¼ 20); 2) monoclonal antibody
against GCGR–treated (mAb REMD2.59) mice (n ¼ 18;
7 mg/kg, subcutaneously, 2 injections at 2 h and 14
days post-MI); and 3) GLC-treated mice (n ¼ 18; 30 mg/
kg body weight in 10% gelatin, 4 times/day for the
first 6 days). For the TAC study, C57BL6 mice at 6 to 7
weeks of age were randomly divided into 2 groups: 5
sham operated as baseline control mice and 29 mice
operated for TAC. The TAC-operated animals were
randomly divided into 3 treatment groups: 1) vehicle
treated (n ¼ 11; antibody dilation buffer A: 10-mM
NaAcetate, 5% sorbitol, 0.004% Tween 20, pH 5.2,
weekly subcutaneous injection); 2) REMD2.59 treated
(n ¼ 7; 7 mg/kg, subcutaneous injection, weekly
started at the onset of TAC); and 3) REMD2.59 therapy
(n ¼ 11; 7 mg/kg, subcutaneous injection, weekly
started 2 weeks after the onset of TAC).
CARDIAC PHYSIOLOGY. For echocardiography,
in vivo cardiac function was assessed by transthoracic
echocardiography (Acuson P300, 18-MHz transducer,
Siemens [Siemens Healthcare Diagnostics, Tarry-
town, New York] and VisualSonics 2100 [Fujifilm
Visualsonics, Toronto, Ontario, Canada]) in conscious
mice for the MI study and anesthetized mice for the
TAC study. From left ventricle short-axis view, an
M-mode echocardiogram was acquired to measure
left ventricular end-systolic and diastolic diameters.
Ejection fraction and fractional shortening were
calculated using onboard software package (Vevo
Imaging System 2100 [Fujifilm Visualsonics]).
TABLE 1 Reverse-Transcription-Polymerase Chain Reaction
Primer Oligonucleotides
Primer Name Sequence
BNP RT-F TAGCCAGTCTCCAGAGCAATTC
BNP RT-R TTGGTCCTTCAAGAGCTGTCTC
18s F TCAAGAACGAAAGTCGGAGG
18s R GGACATCTAAGGGCATCAC
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investigators blinded to treatments. For hemody-
namic measurements, a Mikro-tip catheter (SPR1000,
Millar Instruments, Houston, Texas) was inserted into
the left ventricle. Left ventricular pressure was
recorded with the Powerlab Data Acquisition System
(ADInstruments Inc., Colorado Springs, Colorado) and
calculated into left ventricular developed pressure as
end-systolic pressure minus end-diastolic pressure,
as well as positive maximal left ventricular pressure
derivative (þdp/dtmax) and negative maximal left
ventricular pressure derivative (dp/dtmax) using
Chart 7 software (AD Instruments, Colorado Springs,
Colorado).
HISTOLOGICAL STUDIES. Hearts were fixed with
10% buffered formalin, embedded in paraffin, and
sectioned at 4 mm. One middle longitudinal section
per heart was stained with Masson’s trichrome (HT-
15, Sigma-Aldrich, St. Louis, Missouri). Eight
randomly selected fields (400) from the noninfarct
area in the left ventricle were examined for fibrosis
and myocyte size under a microscope. Each group
comprised 5 to 6 hearts, and a minimum of 40 fields
were analyzed in each group by computerized
planimetry (ImageJ, National Institutes of Health,
Bethesda, Maryland). To assess fibrosis, fibrotic blue
area and whole myocardial area were measured. The
fibrotic area was presented as a percentage of fibrotic
area to the myocardial area. Myocyte size was
measured in cross-sectioned muscle cells. In total,
100 to 150 cells/heart were analyzed based on wheat
germ agglutinin staining. Two methods were used to
assess the size of the infarcted heart. Infarct area was
calculated as a percentage of infarcted ventricular
area to total ventricular area using the front and back
sides of the heart photos. Infarct size was measured
as a percentage of infarcted ventricular wall length to
total ventricular wall length using cardiac sections.
The observer was blinded to the origin of the cardiac
sections.
TUNEL assay was performed with the In-Situ
Apoptosis Detection Kit (Thermo Fisher Scientific,
Waltham, Massachusetts). Briefly, hearts were fixed
by perfusion with 10% formalin solution, embedded in
paraffin, and sectioned at 6 mm. One middle longitu-
dinal section per heart was taken for TUNEL staining.
Proteinase K (20 mg/ml) was added to each slide.
Endogenous peroxidases were inactivated by covering
sections with 2% hydrogen peroxide. After fixation,
sections were incubated with terminal deoxy-
nucleotidyl transferase buffer at 37C for 30 min. Re-
actions were terminated with 1 saline-sodium citrate
buffer. After being washed, slides were incubated withRTU streptavidin-horseradish peroxidase for 30 min.
Positive signal was developed by adding DAB solution.
After counterstained with RTU hematoxylin, slides
were covered by mounting medium and analyzed
under a microscope. Each group comprised 5 to 6
hearts. Eight fields (400) from the infarct area per
heart were analyzed for positive cells and total cells
using computerized planimetry (ImageJ). The degree
of apoptosis was presented as a percentage of positive
cells to total cells.
REAL-TIME POLYMERASE CHAIN REACTION. 1 mg
RNA was used for first-strand complementary DNA
synthesis using Random Primer (Thermo Fisher
Scientific) and SuperScriptII Reverse Transcriptase
(Thermo Fisher Scientific) according to manufac-
turer’s instruction. Real-time polymerase chain
reaction (PCR) was performed using IQ SYBR Green
Supermix (Bio-Rad Laboratories, Hercules, California)
with CFX-96 Real-time PCR Detection System
(Bio-Rad Laboratories) with primers as described in
Table 1.
STATISTICAL ANALYSIS METHODS. We used student
Wilcoxon rank sum test or analysis of variance to
perform statistical analysis between 2 groups or
among multiple groups, and a p value <0.05 was
considered significant. The specific p values are
depicted in the figures according to the following
symbols, unless specified in individual figure legend:
# indicates p < 0.05, * indicates p < 0.01, ** indicates
p < 0.001.
RESULTS
GCGR ANTAGONISM ATTENUATES MI-INDUCED
CARDIAC REMODELING. Eight-week to 10-week-old
C57BL/J6 male mice were operated by permanent oc-
clusion of left coronary artery descending artery and
then randomized into 3 experimental groups, which
were treated with PBS (control group; subcutaneous
injection twice at 2 h, and 14 days post-MI) or mono-
clonal anti-GCGR antibody REMD2.59 (REMD group;
subcutaneous injection of 7 mg/kg twice at 2 h and 14
days post MI) and GLC (GLC group; subcutaneous in-
jection of 30 mg/kg 4 times/day for the first 6 days), as
FIGURE 1 Glucagon and Glucagon Receptor Antagonism in Myocardial Infarction
(A) Illustration of experimental design to investigate the effect of glucagon (GLC) and
REMD2.59 treatment on myocardial infarction (MI). (B) Blood glucose level 14 days after
vehicle (Control) or REMD treatment as indicated. The statistical significance and the
specific p values depicted in this and the following figures are described in the Methods
section according to the following symbols, unless specified for specific comparison
among specific groups: #p < 0.05, *p < 0.01, **p < 0.001. Echo ¼ echocardiography;
PBS ¼ phosphate-buffered saline; s.c. ¼ subcutaneous.
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165illustrated in Figure 1A. REMD2.59 treatment modestly
but significantly reduced fasting blood glucose level,
indicating the expected GLC antagonistic effect of
REMD2.59 in mice (Figure 1B). As shown in Figures 2A
and 2B, in the vehicle-treated control group, histopa-
thology analysis at the end of the experiment period
of 4 weeks post-MI showed approximately 39% infarct
scar size relative to total heart size. In contrast, the
REMD-treated heart showed an average of 32% scar
area and GLC-treated hearts showed an average of
48% scar area. Although GLC-treated hearts trended
to have larger infarct sizes and REMD-treated hearts
trended to smaller infarct sizes, the differences did
not reach statistical significance, indicating that
myocardium sparing may not be the major basis of
protection GCGR effects in the post-MI hearts. The
REMD2.59-treated heart showed a significant reduc-
tion in the apoptotic events detected by TUNEL
(Figures 2C and 2D) as well as the level of myocardial
fibrosis measured by trichrome staining (Figures 2E
and 2F). However, the cellular identities of the
apoptotic cells remain to be determined. Finally,
REMD2.59 treatment also significantly reduced car-
diac hypertrophy versus the vehicle-treated group
based on heart weight (Figure 3A), or myocyte cross-
sectional area measurements (Figure 3B). However,
treatment of unoperated mice with REMD2.59 for 2
weeks did not affect basal heart weight (Figure 3C).
These data support the notion that GCGR antagonism
can prevent and attenuate the onset of pathological
remodeling in response to myocardial injury, by
reducing fibrosis and attenuating cardiomyocyte
pathological hypertrophy.
GCGR ANTAGONISM PRESERVES CARDIAC FUNCTION
AFTER MI. In addition to morphological and histolog-
ical analysis, we measured cardiac function in each
experimental group by both noninvasive echocar-
diogram and catheter based hemodynamic analysis.
As shown in Figures 4A and 4B, a serial echocardio-
gram showed progressive deterioration of systolic
function from 26% fractional shortening at week 1 to
16% at week 4 after MI in the vehicle-treated mice. In
contrast, the REMD2.59 treatment almost completely
preserved cardiac function from 30% fractional
shortening at week 1 to 38% at week 4. In contrast,
the mice treated with GLC showed earlier contractile
dysfunction than the vehicle-treated group, losing
fractional shortening from 26% at week 1 to 17.9% at
week 1 after MI. Consistent with the impact on sys-
tolic function, significant chamber dilation was
observed in the vehicle- and GLC-treated groups,
which was almost completely blunted by REMD2.59
treatment (Figure 4B). Using catheter-based invasivehemodynamic measurements (Figures 4C–E), we
observed that REMD2.59 treatment significantly
elevated left ventricular developed pressure, and
systolic pressure and improved both systolic (þdP/
dtmax; p < 0.05) and diastolic (–dP/dtmax; p ¼ 0.06)
parameters in the post-MI hearts compared with the
vehicle-treated control mice. These data suggest that
GCGR inhibition can prevent loss of cardiac function
in post-MI hearts. It is noted that the mice from he-
modynamic studies had average heart rates (378  94
beats/min, 363  71 beats/min, 431  114 beats/min for
vehicle-, REMD-, and GLC-treated groups, respec-
tively). In contrast, the average heart rates of mice for
the echocardiograph studies were 626  18 beats/min,
657  9 beats/min, and 662  7 beats/min for the same
groups, respectively. Therefore, the hemodynamic
measurements were measured under a significantly
depressed state, likely due to anesthesia. Neverthe-
less, there were no differences in heart rates among
the 3 experiment groups in either measurements,
suggesting that the differences observed in the he-
modynamic or echocardiographic parameters were
not the results of differential degrees of anesthesia
levels.
GCGR INHIBITION ON PRESSURE OVERLOAD–INDUCED
CARDIAC HYPERTROPHY. To demonstrate the applica-
bility of GCGR antagonism therapy to heart failure
with different etiologies, we investigated the impact
of REMD2.59 on pressure overload induced cardiac
hypertrophy, dysfunction, and remodeling. Pressure
overload was induced by TAC as described previously
(33,34) in C57BL/6 male mice 8 to 10 weeks of age
FIGURE 2 Impact of GLC and GLC Receptor Antagonism on Myocardial Infarction
(A) Representative hematoxylin and eosin section of cardiac tissue 4 weeks after MI treated with PBS (Control), GLC, and GLC receptor
antagonist (REMD). (B) Quantification of infarct scar sizes based on histological analysis; group sizes are indicated in each bar graph. (C)
Representative TUNEL staining images of left ventricle with apoptotic cells indicated by arrows. (D) Quantification of percent TUNEL-positive
cells with group sizes indicated. #p < 0.01. (E) Representative trichrome staining of left ventricular tissue. (F) Quantification of fibrotic area
in the noninfarcted left ventricle from each group with group sizes indicated. Abbreviations as in Figure 1.
FIGURE 3 Impact of GLC and GLC Receptor Antagonist on Cardiac Hypertrophy in
Post-Myocardial Infarct Heart
(A) Heart weight (HW) versus body weight (BW) 4 weeks after MI treated with PBS
(Control), GLC, and GLC receptor antagonist (REMD). Groups sizes are indicated. (B)
Myocyte cross-sectional areas (CSA) in left ventricles of the same mouse groups as in
pane A. Group sizes are indicated. ## p< 0.001, #p < 0.01, *p < 0.05. Abbreviations as
in Figure 1.
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166followed by weekly treatment of vehicle or anti-GCGR
antibody (REMD2.59, 7 mg/kg body weight, subcu-
taneous injection) starting at the same time or start-
ing at 2-weeks post TAC (REMD2.59 therapy)
(Figure 5). Compared with the sham-operated group,
TAC induced a significant increase in heart sizes as
demonstrated in histological sections of the left
ventricle, and tissue weights and cardiomyocyte
cross-sectional morphometric data of cardiac cham-
ber weight and the left ventricle (Figure 6). Concur-
rent treatment with REMD2.59 significantly blunted
the increase of heart weight and myocyte enlarge-
ment compared with the TAC group. In contrast,
starting REMD2.59 treatment at 2 weeks post-TAC
(REMD2.59 therapy) failed to block left ventricular
hypertrophy. These data indicate that GCGR inhibi-
tion can prevent the onset of cardiac hypertrophy
induced by pressure overload, but has limited effect
to reverse established cardiac hypertrophy.
GCGR INHIBITION IN PRESSURE OVERLOAD–INDUCED
CARDIAC DYSFUNCTION. Using serial echocardiogram
analysis, we found cardiac function, as measured
from ejection fraction and percent fractional short-
ening, was significantly impaired by chronic pres-
sure overload as early as 2 weeks post-TAC and
deteriorated further at 5 weeks post-TAC (Figure 7),
FIGURE 4 Impact of GLC and GLC Receptor Antagonist on Cardiac Function and Chamber Dilation in Post-Myocardial Heart
(A) Fractional shortening and (B) left ventricular end-systolic dimension (LVESD) in MI hearts treated with PBS (Control; n ¼ 10, blue), GLC
(n ¼ 6, purple), and GLC receptor antagonist (REMD; n ¼ 11; red) at different time points recorded by echocardiogram. #p < 0.05 REMD
versus Control; REMD versus GLC. (C) Left ventricular developed pressure (LVDP). (D) Left ventricular systolic pressure (LVSP). (E) Maximum
pressure derivative (þdP/dtmax) and (F)Minimum pressure derivative (–dP/dtmin) as measured by conductance catheter. Abbreviations as in
Figure 1.
FIGURE 5 Glucagon and Glucagon Antagonism in Pressure-Overload Induced Cardiac
Hypertrophy
Illustration of treatment regiments for pressure overload–induced heart failure by GLC
receptor antagonist either at the onset of the transaortic surgery (transaortic constric-
tion [TAC] þ REMD) or 2 weeks after (TAC þ REMD therapy). Abbreviations as in Figure 1.
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167along with pulmonary congestion (Figure 6B).
Treating mice with REMD2.59 at the onset of pres-
sure overload largely preserved the contractile
function in the pressure-overloaded hearts with
ejection fraction and percent fractional shortening
statistically unchanged comparing with the sham-
operated mice at 5 weeks post-TAC (Figure 7).
Starting REMD2.59 treatment 2 weeks after TAC,
when functional impairment had already man-
ifested, blunted further deterioration comparing to
the vehicle-treated group. Using speckle tracking–
based tissue-strain analysis from echocardiographic
images (Figure 8), we observed that REMD2.59
treatment from the onset of TAC prevented the
pressure overload–induced systolic and diastolic
dysfunction as demonstrated in both systolic strain
and diastolic strain rate. In contrast, REMD2.59
treatment starting 2 weeks post-TAC had limited
success to reverse these parameters. The car-
dioprotective effect of REMD2.59 treatment was also
manifested in significantly blunted pulmonary
congestion (Figure 6B). All these evidences suggest
that GCGR antagonism exerts significant protectionagainst pressure overload induced cardiac dysfunc-
tion and blunts progression of heart failure.
GCGR ANTAGONISM ON PATHOLOGICAL REMOD-
ELING IN THE PRESSURE-OVERLOADED HEART. As a
common feature of cardiac remodeling, chronic
FIGURE 6 Impact of GLC Receptor Antagonist on Cardiac Hypertrophy
(A) Representative histological section of ventricle by hematoxylin and eosin staining of the heart from each treatment group as indicated.
(B) Tissue weight measured at week 5 post-TAC from each treatment group as indicated, including HW versus BW (HW/BW), left ventricle
weight versus BW (LVW/BW), and lung weight versus BW (LW/BW). *p < 0.05 versus sham. (C) Representative images of tissue section of left
ventricles stained with wheat germ agglutinin from each treatment group as indicated. (D) Quantification of cardiomyocyte cross-sectional
area in left ventricles of hearts from different treatment groups as indicated. *p< 0.05 versus Control, #p< 0.05 versus TAC. Abbreviations
as in Figures 1, 3, and 5.
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168pressure overload induced significant level of cardiac
fibrosis, as detected by trichrome staining (Figures 9A
and 9B) and the expression of a pathological marker
gene B-type natriuretic peptide measured by quanti-
tative reverse transcription PCR (Figure 9C).
REMD2.59 treatment started either at the onset of
pressure overload or 2 weeks post-TAC completely
blocked these changes. Therefore, GCGR inhibition
can significantly block pathological remodeling instressed heart in terms of extracellular matrix
remodeling or gene expression.
DISCUSSION
In this report, the therapeutic effect of a GCGR
antagonistic antibody REMD2.59 was tested in 2
mechanistically divergent disease models of heart
failure without confounding defects in global
FIGURE 7 Functional Impact of GLC Receptor Antagonist on Contractile Function Measured by Echocardiogram
(A) Ejection fraction and (B) fractional shortening were measured at basal (week 0), 2 weeks post-TAC (week 2) and 5 weeks post-TAC from
each treatment group as indicated. *p < 0.05 TAC versus TAC þ REMD; #p < 0.05 TAC versus TAC þ REMD therapy. Abbreviations as in
Figures 1 and 5.
FIGURE 8 Impact of GLC Receptor Antagonist on Pressure-Overloaded Heart Measured by Tissue Strain
(A) Representative images of long-axis echo recording (left panel), with cross-sectional segment synchronicity map (middle panels), and
radial and longitudinal endocardial strain (right panel). (B) Average systolic radial strain and (C) average diastolic longitudinal strain rates at
week 0, 2, and 5 post-TAC from each experimental group as indicated. *p < 0.05 Control versus TAC; #p < 0.05 TAC versus TACþREMD; $p <
0.05 Control versus TAC þ REMD therapy. Abbreviations as in Figures 1 and 5.
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FIGURE 9 Impact of GLC Receptor Antagonist on Pathological Remodeling
(A) Representative images of trichrome-stained tissue section from hearts of different experimental groups as indicated. (B) Quantification of
cardiac fibrosis from panel A. (C) messenger RNA expression level of B-type natriuretic peptide as measured by quantitative reverse tran-
scriptase polymerase chain reaction in heart tissue from different experimental groups as indicated. n ¼ 3/group. #p < 0.05 versus Sham.
Abbreviations as in Figures 1 and 5.
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170metabolism. Based on histological and functional
analyses in both MI-injured and pressure-overloaded
hearts, REMD2.59 treatment showed significant pro-
tection against cardiac hypertrophy and fibrosis
remodeling with better preserved contractile func-
tion. These findings support a broadly applicable
cardioprotective effect of GCGR inhibition against
heart failure with different etiologies. As both these
pathological stressors are imposed specifically and
directly on heart rather in a systemic fashion, the
observed cardioprotection of REMD2.59 is likely the
result of its direct impact on GCGR signaling in car-
diomyocytes rather than its impact on global glucose
metabolic activities. This observation is consistent
with the previous observations made in the
cardiomyocyte-specific GCGR knockout mice, which
have demonstrated the cardioprotective effect of
GCGR antagonism against myocardial infarction in a
receptor-dependent and cardiomyocyte cell-
autonomous manner (29,32).
GLC and insulin are both pancreatic but counter-
balancing hormones important to maintain systemic
glucose regulation. GLC exerts its function via a
peptide G protein–coupled receptor, GCGR. The ca-
nonical GCGR-mediated signaling involves classic G
protein–coupled cAMP-dependent protein kinase A
activation in hepatocytes, leading to induction of
gluconeogenesis and glycogen catabolism, while
inhibiting glycolysis (7,35). In addition to its pre-
dominant expression in liver, GCGR is also expressedat modest to low levels in the kidney, heart, pancreas,
and many other tissues (3,8,36). Although G protein–
coupled canonical signaling for GLC is well estab-
lished in hepatocytes, other mechanisms involving
intracellular calcium regulation have also been re-
ported in nonhepatocytes including cardiomyocytes
(3,10,28,36). In this report, we investigated GCGR in-
hibition in 2 mechanistically divergent disease
models (i.e., myocardial infarction vs. pressure
overload), the treatment resulted in similar car-
dioprotective effects against a broad spectrum of
sequential pathological features in the failing heart,
including cardiomyocyte hypertrophy, marker gene
induction, interstitial fibrosis, and most importantly,
cardiomyocyte contractile dysfunction. Apparently,
GCGR antagonism is affecting cellular processes
shared by different etiologies of cardiac pathology,
including diabetes (32), ischemic injury, and me-
chanical overload. It is conceivable that abnormal
GCGR activity may impact on cellular metabolism and
energetic status via AMPK-dependent modulation in
working heart as shown by Sharma et al. (32). How-
ever, our understanding to noncanonical signaling
mechanism of GCGR is still very limited, and more
studies are needed to illustrate the mechanistic basis
of GCGR antagonism–mediated cardioprotection in
response to different pathological stressors and en-
ergy homeostasis in failing hearts.
It is important to note that when REMD2.59 was
applied 2 weeks after the onset of pressure overload,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Systemic treat-
ment of an antibody-based GCGR antagonist is currently in phase
I and II clinical trials for type 1 and type 2 diabetes. The current
study demonstrates for the first time that systemic treatment of
GCGR antagonist can also exert potent cardioprotection against
ischemic injury in the heart, and prevents pathological remod-
eling and heart failure induced by mechanic overload in nonob-
ese and nondiabetic mice.
TRANSLATIONAL OUTLOOK: Systemic treatment of GCGR
antagonist can be considered as a potential therapy for heart
failure with different etiologies without concurrent metabolic
disorders.
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171GCGR antagonism no longer had any significant
impact on cardiac hypertrophy, but still preserved
the residual functions of the heart (Figures 6 and 7).
This is consistent with previously reported observa-
tion that cardiomyocyte hypertrophy is established
rather early in response to pressure overload while
contractile dysfunction and fibrotic remodeling will
continue to manifest (33). Our results highlight the
potential limitation in the therapeutic window for
heart failure. Nevertheless, REMD treatment can halt
the further progression of heart failure and remod-
eling despite the limitation that GCGR antagonism
may not be sufficient to reverse established cardiac
hypertrophy and to fully restore contractile function.
It is clear that more studies will be needed to fully
establish the therapeutic efficacy of GCGR antago-
nism. Clinically relevant large animal models with
established heart failure will be needed, and longer-
term treatment and better outcome-based measure-
ments (e.g., death and exercise tolerance) will be
required.
Extensive pharmacological and structural analysis
shows GCGR antibody REMD-477 competitively
blocks GLC binding to the GCGR with 30-pM binding
affinity, and can fully inhibit the receptor activity at
low nanomolar concentrations in cells (14,17,20).
Functionally identical to REMD-477, REMD2.59 is a
surrogate human antibody specifically generated for
chronical preclinical studies in rodents and primates.
Unlike previous small-molecule approaches (30),
REMD-477 does not have deleterious effects on
serum lipid profiles (11,12,19,21,31) in both ongoing
clinical trials in diabetes patients. In short, the anti-
GCGR antibody as tested here offers a novel and
powerful therapeutic tool to effectively and specif-
ically inhibit GCGR with proven record of clinical
safety and efficacy at molecular and metabolic
levels.
Several other diabetic therapies, including GLC-
like peptide-1 agonists (37,38), dipeptidyl peptidase
4 inhibition (39), and sodium glucose cotransporter 2inhibitors (40,41), have demonstrated various de-
grees of cardiovascular benefits along with amelio-
rated metabolic defects in glucose homeostasis. Yet,
not all glucose-lowering therapies have such signifi-
cant cardiovascular protective effects as sodium
glucose cotransporter 2 inhibition (42–46). It is also
unclear if these therapies will be efficacious for
common forms of heart failure without the con-
founding metabolic disorders. Our current study in 2
heart failure disease models free from systemic
metabolic disorders further supports that GCGR in-
hibition may be repurposed as an effective therapy
for common forms of heart failure.
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